Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD44V6 expression in human colorectal carcinoma

D Coppola1, M Hyacinthe, L Fu

  • 1Department of Pathology, University of South Florida-Moffitt Cancer Center, Tampa 33612, USA.

Human Pathology
|July 4, 1998
PubMed
Summary

CD44 variant 6 (CD44V6) is highly expressed in colorectal adenomas and carcinomas but diminishes in metastases. This suggests CD44V6 loss may be linked to tumor cell migration and reduced metastatic potential in colorectal cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Oncogene·2024
Same author

Editorial Expression of Concern: Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer.

Oncogene·2024
Same author

Ground deformation reveals the scale-invariant conduit dynamics driving explosive basaltic eruptions.

Nature communications·2021
Same author

Analysis of the immune landscape of small bowel neuroendocrine tumors.

Endocrine-related cancer·2018
Same author

Recombinant activated factor VII in approved indications: Update on safety.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunohistochemistry

Background:

  • CD44 is a transmembrane glycoprotein involved in cell adhesion, with standard and variant forms.
  • The CD44 variant 6 (CD44V6) isoform has been implicated in modulating tumor cell metastatic potential.
  • Investigating CD44V6 as a prognostic biomarker in colorectal cancer is crucial for understanding disease progression.

Purpose of the Study:

  • To analyze the expression and distribution of CD44V6 in colorectal cancer tissues.
  • To evaluate the potential of CD44V6 as a prognostic antigen in colorectal cancer.
  • To correlate CD44V6 expression with tumor stage, type, and metastatic status.

Main Methods:

  • Immunohistochemical analysis of CD44V6 expression on formalin-fixed, paraffin-embedded colorectal cancer tissues.

Related Experiment Videos

  • Use of the VFF7 monoclonal antibody against CD44V6 exon sequence.
  • Western blot immunoprecipitation technique for protein expression analysis in selected cases.

    • Main Results:

    • CD44V6 immunoreactivity was detected in 100% of adenomas (ADs) and 91% of carcinomas (CAs).
    • Expression was significantly weaker in metastases (MTs), with only 38% showing weak staining.
    • Moderate to strong CD44V6 staining was observed in 49% of ADs and 11% of CAs, predominantly membranous in ADs and cytoplasmic in MTs.
    • No correlation was found between CD44V6 expression and tumor type, stage, or patient survival.

    Conclusions:

    • CD44V6 is predominantly expressed in colorectal adenomas and carcinomas.
    • The decrease in CD44V6 expression in metastases suggests its potential loss during tumor cell migration.
    • CD44V6 may not serve as a direct prognostic antigen for overall survival in colorectal cancer but indicates changes in cell adhesion during metastasis.